Global  

Celebrating 10 Years of Trusted News Discovery
One News Page
> >

Imugene welcomes receipt of US Department of Defense grant for City of Hope cancer researchers

Proactive Investors Wednesday, 23 October 2019
Imugene Limited (ASX:IMU) has revealed that City of Hope researchers Yanghee Woo, MD and Yuman Fong, MD have received a $564,173 US Department of Defense Grant for the oncolytic virotherapy CF33 in gastric cancer. Background The CF33 oncolytic virus was developed at City of Hope, a world-renowned independent research and treatment centre for cancer, diabetes and other life-threatening diseases based in California. Imugene’s proposal to license CF33 from City of Hope is awaiting satisfaction of customary conditions precedent and shareholder approval at the Extraordinary General Meeting (EGM) to be held on November 18, 2019. Focus on gastric cancer The grant focuses on the area of stomach (gastric) cancer (GC), a disease that disproportionately affects US military service members, veterans, and their beneficiaries who have increased exposure to hazardous environmental risk factors, such as H. pylori, Epstein-Barr viral infections, radiation, and tobacco smoking. Peritoneal carcinomatosis (PC) is a fatal evolution of GC for which there is no effective treatment. Across military families and the general population, over 60% of all patients with GC will develop peritoneal disease as the most common manifestation of recurrence or metastatic presentation. The progression of primary GC to PC is facilitated by the unique peritoneal tumour microenvironment, where metastatic peritoneal seeding requires evasion of anti-tumour immunity and maintenance of a highly immunosuppressive microenvironment. The researchers rationalize that a combined approach using Imugene’s proposed license for novel oncolytic virus CF33 armed to express an anti-PD-L1 antibody as immune modulator could specifically kill cancer cells, convert the immunologically ‘cold’ environment of PC into a ‘hot’ environment, and enhance the overall efficacy of GC therapy. Expanding CF33 development Imugene managing director and CEO Leslie Chong said: “Imugene and City of Hope are committed to help improve the length and quality of life for patients with gastric cancer. “We congratulate Dr. Yanghee Woo and Dr. Yuman Fong on receiving this sizable grant. “It is an honour to work with the prestigious and prolific team at City of Hope to expand the development of CF33”.
0
shares
ShareTweetSavePostSend
 
Credit: CBS2 LA - Published < > Embed
News video: Cancer Drug Breakthrough Saves Southland Woman's Life

Cancer Drug Breakthrough Saves Southland Woman's Life 02:00

The cancer drug Herceptin helped a local woman beat breast cancer. Lesley Marin reports.

Recent related videos from verified sources

City of Cincinnati announces solar energy project [Video]City of Cincinnati announces solar energy project

A new green initiative by the City of Cincinnati will help improve air quality by cutting back on emissions from coal-burning power plants, and help the city complete its pledge to move towards using..

Credit: WCPO Cincinnati     Duration: 01:49Published

Olathe family hoping for miracle for 5-year-old with inoperable cancer [Video]Olathe family hoping for miracle for 5-year-old with inoperable cancer

Hudson Sands, 5, has diffuse intrinsic pontine glioma, or DIPG, an incurable and inoperable form of cancer. His parents, Todd and Stacey Sands, hope their son will qualify for a clinical trial in..

Credit: 41 Action News     Duration: 02:19Published


Recent related news from verified sources

Ready to get away? These are KCI's most popular travel destinations

These airports are the top destinations for travelers leaving Kansas City International Airport (Code: MCI) in 2019. The top destinations are measured by average...
bizjournals

Imugene appoints distinguished physician and scientist to the Scientific Advisory Board

Imugene Ltd (ASX:IMU) has appointed professor Prasad S Adusumilli to its newly formed oncolytic virotherapy (OV) Scientific Advisory Board (SAB). Adusimilli is...
Proactive Investors

You Might Like


Tweets about this

Environmentally friendly: One News Page is hosted on servers powered solely by renewable energy
© 2019 One News Page Ltd. All Rights Reserved.
About us  |  Contact us  |  Disclaimer  |  Press Room  |  Terms & Conditions  |  Content Accreditation
 RSS  |  News for my Website  |  Free news search widget  |  In the News  |  DMCA / Content Removal  |  Privacy & Data Protection Policy
How are we doing? FeedbackSend us your feedback  |   LIKE us on Facebook   FOLLOW us on Twitter  •  FOLLOW us on Pinterest
One News® is a registered trademark of One News Page Ltd.